Pegylated recombinant human megakaryocyte growth and development factor suppresses the development of megakaryoblastic leukemia in mice

Kazunori Shibuya, Tomoaki Kuwaki, Hiromichi Akahori, Takashi Kato, Hiroshi Miyazaki

    Research output: Contribution to journalArticle

    1 Citation (Scopus)

    Abstract

    We examined the effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on the development of L-8057, a murine megakaryoblastic leukemia that expresses the thrombopoietin receptor c-Mpl, in mice. PEG-rHuMGDF administration prolonged survival of L-8057 leukemic mice, in which L-8057 cell growth in the spleen was decreased. L-8057 cells harvested from PEG-rHuMGDF-treated leukemic mice had decreased ability to generate leukemic colonies in vitro as well as to induce leukemia in vivo. PEG-rHuMGDF administration also resulted in prolonged survival of mice transplanted with a c-Mpl-expressing erythroleukemia, but had no effect on survival of mice transplanted with a myeloblastic leukemia that does not possess c-Mpl. Thus, PEG-rHuMGDF suppresses the development of c-Mpl-expressing leukemia in vivo in mice.

    Original languageEnglish
    Pages (from-to)941-946
    Number of pages6
    JournalLeukemia Research
    Volume28
    Issue number9
    DOIs
    Publication statusPublished - 2004 Sep

    Fingerprint

    Leukemia
    Thrombopoietin Receptors
    Leukemia, Erythroblastic, Acute
    polyethylene glycol-recombinant human megakaryocyte growth and development factor
    Spleen
    Growth

    Keywords

    • acute myelogenous leukemia
    • AML
    • bovine serum albumin
    • BSA
    • FCS
    • fetal calf serum
    • L-CFU
    • leukemia colony-forming unit
    • PEG-rHuMGDF
    • pegylated recombinant human megakaryocyte growth and development factor
    • thrombopoietin
    • TPO
    • WBC
    • white blood cell

    ASJC Scopus subject areas

    • Cancer Research
    • Hematology
    • Oncology

    Cite this

    Pegylated recombinant human megakaryocyte growth and development factor suppresses the development of megakaryoblastic leukemia in mice. / Shibuya, Kazunori; Kuwaki, Tomoaki; Akahori, Hiromichi; Kato, Takashi; Miyazaki, Hiroshi.

    In: Leukemia Research, Vol. 28, No. 9, 09.2004, p. 941-946.

    Research output: Contribution to journalArticle

    Shibuya, Kazunori ; Kuwaki, Tomoaki ; Akahori, Hiromichi ; Kato, Takashi ; Miyazaki, Hiroshi. / Pegylated recombinant human megakaryocyte growth and development factor suppresses the development of megakaryoblastic leukemia in mice. In: Leukemia Research. 2004 ; Vol. 28, No. 9. pp. 941-946.
    @article{9f46e54a6c394da4b90bb825c727f762,
    title = "Pegylated recombinant human megakaryocyte growth and development factor suppresses the development of megakaryoblastic leukemia in mice",
    abstract = "We examined the effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on the development of L-8057, a murine megakaryoblastic leukemia that expresses the thrombopoietin receptor c-Mpl, in mice. PEG-rHuMGDF administration prolonged survival of L-8057 leukemic mice, in which L-8057 cell growth in the spleen was decreased. L-8057 cells harvested from PEG-rHuMGDF-treated leukemic mice had decreased ability to generate leukemic colonies in vitro as well as to induce leukemia in vivo. PEG-rHuMGDF administration also resulted in prolonged survival of mice transplanted with a c-Mpl-expressing erythroleukemia, but had no effect on survival of mice transplanted with a myeloblastic leukemia that does not possess c-Mpl. Thus, PEG-rHuMGDF suppresses the development of c-Mpl-expressing leukemia in vivo in mice.",
    keywords = "acute myelogenous leukemia, AML, bovine serum albumin, BSA, FCS, fetal calf serum, L-CFU, leukemia colony-forming unit, PEG-rHuMGDF, pegylated recombinant human megakaryocyte growth and development factor, thrombopoietin, TPO, WBC, white blood cell",
    author = "Kazunori Shibuya and Tomoaki Kuwaki and Hiromichi Akahori and Takashi Kato and Hiroshi Miyazaki",
    year = "2004",
    month = "9",
    doi = "10.1016/j.leukres.2003.12.007",
    language = "English",
    volume = "28",
    pages = "941--946",
    journal = "Leukemia Research",
    issn = "0145-2126",
    publisher = "Elsevier Limited",
    number = "9",

    }

    TY - JOUR

    T1 - Pegylated recombinant human megakaryocyte growth and development factor suppresses the development of megakaryoblastic leukemia in mice

    AU - Shibuya, Kazunori

    AU - Kuwaki, Tomoaki

    AU - Akahori, Hiromichi

    AU - Kato, Takashi

    AU - Miyazaki, Hiroshi

    PY - 2004/9

    Y1 - 2004/9

    N2 - We examined the effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on the development of L-8057, a murine megakaryoblastic leukemia that expresses the thrombopoietin receptor c-Mpl, in mice. PEG-rHuMGDF administration prolonged survival of L-8057 leukemic mice, in which L-8057 cell growth in the spleen was decreased. L-8057 cells harvested from PEG-rHuMGDF-treated leukemic mice had decreased ability to generate leukemic colonies in vitro as well as to induce leukemia in vivo. PEG-rHuMGDF administration also resulted in prolonged survival of mice transplanted with a c-Mpl-expressing erythroleukemia, but had no effect on survival of mice transplanted with a myeloblastic leukemia that does not possess c-Mpl. Thus, PEG-rHuMGDF suppresses the development of c-Mpl-expressing leukemia in vivo in mice.

    AB - We examined the effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on the development of L-8057, a murine megakaryoblastic leukemia that expresses the thrombopoietin receptor c-Mpl, in mice. PEG-rHuMGDF administration prolonged survival of L-8057 leukemic mice, in which L-8057 cell growth in the spleen was decreased. L-8057 cells harvested from PEG-rHuMGDF-treated leukemic mice had decreased ability to generate leukemic colonies in vitro as well as to induce leukemia in vivo. PEG-rHuMGDF administration also resulted in prolonged survival of mice transplanted with a c-Mpl-expressing erythroleukemia, but had no effect on survival of mice transplanted with a myeloblastic leukemia that does not possess c-Mpl. Thus, PEG-rHuMGDF suppresses the development of c-Mpl-expressing leukemia in vivo in mice.

    KW - acute myelogenous leukemia

    KW - AML

    KW - bovine serum albumin

    KW - BSA

    KW - FCS

    KW - fetal calf serum

    KW - L-CFU

    KW - leukemia colony-forming unit

    KW - PEG-rHuMGDF

    KW - pegylated recombinant human megakaryocyte growth and development factor

    KW - thrombopoietin

    KW - TPO

    KW - WBC

    KW - white blood cell

    UR - http://www.scopus.com/inward/record.url?scp=3242705731&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=3242705731&partnerID=8YFLogxK

    U2 - 10.1016/j.leukres.2003.12.007

    DO - 10.1016/j.leukres.2003.12.007

    M3 - Article

    C2 - 15234571

    AN - SCOPUS:3242705731

    VL - 28

    SP - 941

    EP - 946

    JO - Leukemia Research

    JF - Leukemia Research

    SN - 0145-2126

    IS - 9

    ER -